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of Bone Marrow-Derived Mononuclear Cells
From Patients With Cardiovascular Disease
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Reinier A. Boon, PHD,* Ruxandra Farcas, PHD,* Yosif Manavski, MSC,* Yi-Gang Li, MD,†
Birgit Assmus, MD,‡ Andreas M. Zeiher, MD,‡ Stefanie Dimmeler, PHD*
Frankfurt, Germany; and Shanghai, China
Objectives This study evaluated the regulation and function of micro-RNAs (miRs) in bone marrow–mononuclear cells
(BMCs).
Background Although cell therapy with BMCs may represent a therapeutic option to treat patients with heart disease, the
impaired functionality of patient-derived cells remains a major challenge. Small noncoding miRs post-
transcriptionally control gene expression patterns and play crucial roles in modulating cell survival and function.
Methods Micro-RNAs were detected by miR profiling in BMCs isolated from healthy volunteers (n  6) or from patients
with myocardial infarction (n  6), and the results were confirmed by polymerase chain reaction (PCR) in a
larger cohort (n  37). The function of selected miRs was determined by gain-of-function studies in vitro and by
locked nuclear acid (LNA) modified inhibitors in vitro and in vivo.
Results We identified several miRs that are up-regulated in BMCs from patients with myocardial infarction compared
with BMCs from healthy controls, including the pro-apoptotic and antiproliferative miR-34a and the hypoxia-
controlled miR-210. Inhibition of miR-34 by LNA-34a significantly reduced miR-34a expression and blocked hy-
drogen peroxide–induced cell death of BMC in vitro, whereas overexpression of miR-34a reduced the survival of
BMCs in vitro. Pre-treatment of BMCs with LNA-34a ex vivo significantly increased the therapeutic benefit of
transplanted BMCs in mice after acute myocardial infarction (AMI).
Conclusions These results demonstrate that cardiovascular disease modulates the miR expression of BMCs in humans. Re-
ducing the expression of the pro-apoptotic miR-34a improves the survival of BMCs in vitro and enhances the
therapeutic benefit of cell therapy in mice after AMI. (BMC Registry, NCT00962364; Progenitor Cell Therapy in
Dilative Cardiomyopathy, NCT00284713) (J Am Coll Cardiol 2012;59:2107–17) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.033Cell therapy is a promising option to improve neovascular-
ization and repair after ischemia. Transplantation of various
adult and embryonic stem cells was shown to augment
contractile function after acute myocardial infarction
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2012, accepted February 18, 2012.(AMI). Particularly, several subsets of bone marrow–derived
cells (BMCs), including hematopoietic progenitor cells, endo-
thelial progenitor cells, and mesenchymal stem cells, improved
recovery after ischemia (1–4) most likely due to an effect on
vascularization of the ischemic tissue (5). Based on these
studies, clinical trials tested the effects of BMCs as well as
selected subpopulations to treat patients with ischemic disease.
Intracoronary infusion of BMCs in patients with AMI im-
proved ejection fraction and prevented left ventricular remod-
eling in most, but not all, studies (6). However, the extent of
improvement was variable between trials, and the benefit of cell
therapy with BMCs particularly in chronically ill patients was
modest (7). One reason underlying the modest improvement
of cardiac function by cell therapy may relate to the use of the
patients’ own cells, which are partially compromised in func-
tion by the exposure to risk factors. Age, concomitant disease
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Micro-RNAs and Cell Therapy June 5, 2012:2107–17(e.g., diabetes), and heart failure
were shown to impair the func-
tionality of the patients’ own cells
(8–10). The mechanisms underly-
ing the dysfunction are multiple and,
for example, include the inhibition
of endothelial nitric oxide synthase
expression and dysregulation of the
balance between nitric oxide and
reactive oxygen species (11,12) and
the activation of protein kinases
(such as p38 mitogen-activated pro-
tein kinase) in diabetic patient-
derived cells (13).
Micro-RNAs (miRs) are small
noncoding RNAs that recently
emerged as key epigenetic regula-
tors that control self-renewal and
differentiation of stem cells (14,15)
and modulate the function of pro-
angiogenic BMCs (16). Moreover,
they play a crucial role particularly
during pathophysiological stress
conditions in the heart as well as in
the vasculature (for review, see
[17]). Micro-RNAs bind to up to
hundreds of target genes and induce mRNA degradation or
block translation of the targeted mRNA, thereby modulating
the gene expression patterns.
We determined the regulation of the miR expression
profile in BMCs isolated from patients with heart disease
compared with healthy volunteers and elucidated the func-
tion of the dysregulated miRs. We demonstrated that
several pro-apoptotic and senescence associated miRs, such
as miR-34a (18,19) and let-7 family members (20), as well
as the hypoxia-controlled miR-210 (21), are increased in
BMCs isolated from patients with acute myocardial infarc-
tion or chronic heart failure. Inhibition of 1 of the dysregu-
lated miRs, namely miR-34a, reduced cell death of BMCs
in vitro and improved the functional capacity of BMCs to
restore cardiac function in a mouse model of AMI in vivo.
Methods
Patient characteristics. Bone marrow aspirates were ob-
tained from healthy volunteers without any evidence of
coronary artery disease by history and physical examination,
or from patients undergoing intracoronary infusion of
BMCs for the treatment of AMI or ischemic cardiomyop-
athy (ICM) (time from last myocardial infarction 3
months), or heart failure without coronary artery disease
(dilated cardiomyopathy [DCM]) within our clinical trials
or an ongoing registry. The ethics review board of Goethe
University (Frankfurt, Germany), approved the protocols,
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
ANOVA  analysis of
variance
BMC  bone
marrow–derived
mononuclear cell
CDK  cyclin-dependent
kinases
DCM  dilated
cardiomyopathy
ICM  ischemic
cardiomyopathy
LNA  locked nuclear acid
miR  micro-RNA
MSP  methylation-specific
PCR
PCR  polymerase chain
reaction
SDF  stromal cell–derived
factor
WMSI  wall motion score
indexand the studies are registered with www.clinicaltrials.gov(NCT00962364 and NCT00284713). Written informed
onsent was obtained from each donor and patient.
ell isolation. BMCs were isolated by Ficoll density gra-
ient centrifugation as previously described (7,22).
icro-RNA array. Total RNA was isolated with miRNeasy
its from Qiagen (Hilden, Germany). The expression of
ature human miRs was determined by human miR mi-
roarrays (DNAvision, Charleroi, Belgium). Murine miRs
solated from BMCs of old (18 month) or young (10 weeks)
ice were detected by the Agilent microarray (DNAvision).
or confirmation of the results, real-time polymerase chain
eaction (PCR) was performed using commercially available
aq man PCR primers on an Applied Biosystems StepOne-
lus (Carlsbad, California). Expression was normalized to
mall nucleolar RNA U48. The relative expression is calcu-
ated using the formula 2–Ct.
Micro-RNA inhibition and overexpression. Micro-RNAs
were inhibited by locked nucleic acid (LNA) modified
antisense miRs (“in vivo LNA microRNA Inhibitors”;
Exiqon, Vedbæk, Denmark) with the following sequences:
LNA-Co: ACGTCTATACGCCCA; and LNA-34a:
AGCTAAGACACTGCC. LNA inhibitors were incu-
bated with BMCs without any transfection reagent. For
overexpression, BMCs were transfected with pre-miR-34a
(5 nM) or pre-miR-negative control (5 nM) (Ambion,
Carlsbad, California) using the Nucleofector Device
(Amaxa, Gaithersburg, Maryland).
Invasion. After incubation of BMCs with LNA, a total of
1  106 BMCs were resuspended in 250 l medium and
placed in the upper chamber of a modified Boyden chamber
filled with Matrigel (BioCoat invasion assay, 8-m pore
ize; Becton Dickinson, Franklin Lakes, New Jersey). Then,
he chamber was placed in a 24-well culture dish containing
00 l x-vivo 10 medium. For some experiments, 100
ng/ml stromal cell–derived factor (SDF)-1 was added to the
lower chamber. After 24 h of incubation at 37°C, transmi-
grated cells were counted. Invasion assays were run in
duplicates.
Viabililty. BMCs (2  106) were incubated with the miR
nhibitors or phosphate-buffered saline, and cell death was
nduced with 200 M hydrogen peroxide for 12 hours. In
he starvation-induced cell death study, 2  106 BMCs
were incubated with the miR inhibitors or phosphate-
buffered saline with or without 2% fetal calf serum (FCS)
for 48 h. Dead cells were counted after incubation with
Trypan blue. The percentage of dead cells was calculated by
dividing the number of Trypan blue-positive cells by the
number of total cells. Alternatively, pre-miR-34a was over-
expressed, and cell death was quantified using the same
method. Representative pictures of Trypan blue-positive
cells were taken with a light microscope at 20
magnification.
DNA methylation. Micro-RNA-34a promoter DNA
methylation was determined using methylation specific
primers after bisulfite conversion of DNA (23). In brief,
bisulfite treatment of 500 ng gDNA was performed using
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Figure 1 Expression Profiling of Micro-RNAs
Expression of micro-RNAs (miRs) in patients with myocardial infarction (n  6) compared with healthy controls (n  6). (A) The M/A plot shows the distribution of the
“Patient”/“Control” intensity ratio (‘M’) plotted by the average intensity (‘A’) for each miRNA. Hybridization probes for upregulated miRs (p 0.05) are shown in red.
(B) Micro-RNA expression is given as miR expression in patients versus bone marrow–mononuclear cells in healthy controls. Mean  SEM, *p 0.05 patients versus
healthy controls (1-way analysis of variance).
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Micro-RNAs and Cell Therapy June 5, 2012:2107–17the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany),
followed by the methylation-specific PCR (MSP) with the
following sequences (MSP-34a-m: Forward primer, GGT
TTT GGG TAG GCG CGT TTC; Reverse primer, TCC
TCA TCC CCT TCA CCG CCG; MSP-34a-u: Forward
primer, TTG GTT TTG GGT AGG TGT GTT TT;
Reverse primer, AAT CCT CAT CCC CTT CAC CAC
CA). Then, 10 and 20 l of MSP products were separated
y electrophoresis on 1.5% agarose gels, and results were
isualized under ultraviolet light after staining with Medori
reen.
estern blot. For Western blot analysis, BMCs were lysed
ith radioimmunoprecipitation assay (RIPA) buffer (Sigma
unich, Germany) supplemented with protease inhibitor
Roche, Penzberg, Bavaria, Germany). After incubation for
5 min on ice, cell lysates were sonicated for 5 s on ice.
hen, the cell lysates were digested with DNase (Qiagen)
or 30 min on ice and then centrifuged for 15 min at
4,000g and 4°C. Protein content of the samples was
etermined according to the Bradford method. Proteins
ere loaded onto sodium dodecyl sulfate polyacrylamide
els and blotted onto polyvinylidene fluoride membranes
Millipore, Schwalbach, Germany).
Membranes were blocked in Tris-buffered saline-T containing
% nonfat dry milk and incubated with specified primary anti-
odies against CDK4 (1/500; Santa Cruz, Heidelberg, Germany)
nd CCND1 (1/500; Santa Cruz) overnight at 4°C. Horseradish
Patient Characteristic (Confirmation Cohort)Table 1 Patient Characteristic (Confirmation Cohort)
Health Condition
HF Patien
ICM AMI
n 11 8
Risk factors
Age (yrs) 66.5 3 64.1 3
Male 10 7
Hypertension 10 5
Hypercholesterolemia 7 2
Diabetes 3 2
Family history 3 2
Smoking 4 3
Medications
ACE inhibitor/ARB 10 5
Beta-blocker 11 6
Statins 10 5
ASS 7 5
Clopidogrel 1 5
Condition
Time from AMI (months) 171.5 28.7
Time from AMI (days) 5.6 1.
NYHA functional class I/II/III/IV 2/4/5/0 3/2/3/0
EF (%) 32.9 2.7 38.7 4.
NT-proBNP (pg/ml)
Median 862 829
Interquartile range 706–2,451 306–3,91
Values are n or mean  SD, unless otherwise indicated.
ACE  angiotensin-converting enzyme; AMI  acute myocardial infarction; ARB  angiotensin recep
C  healthy controls; HF  heart failure; ICM  ischemic cardiomyopathy; n.d.: not determined; NT-proeroxidase (HRP)-conjugated secondary antibody was pur-
hased from GE Healthcare (Munich Germany). Protein
ands were visualized with electrochemiluminescent sub-
trate reagent according to the manufacturer’s protocol
GE Healthcare).
cute myocardial infarction model. AMI was induced in
ale nu/nu mice (8 to 10 weeks old; Charles River,
ulzfeld, Germany) by permanent ligation of the left ante-
ior coronary artery under mechanical ventilation and anes-
hesia with isoflurane and analgesia with bupivacaine (1
g/kg, 0.25% bupivacaine 1 to 3 drops on the incision area)
nd carprofen (5 mg/kg subcutaneously) perioperatively and
very 24 h for 3 days post-operatively. BMCs (2  106)
were incubated with 500 nM LNA-34a or PBS for 24
hours. After washing, cells were re-suspended and 1  106
BMCs were injected in a total volume of 50 l PBS
ntramuscularly at 4 points in the border zone distal to the
igation of the coronary artery immediately after induction
f the myocardial infarction. Cardiac function was deter-
ined by high resolution echocardiography (Vevo770 small
nimal micro-ultrasound system, VisualSonics, Toronto,
ntario, Canada) at day 0 and day 14. Wall motion score
ndex (WMSI) was analyzed using the 16-segment model
ased on 3-short axis views (4 apical, 6 middle, and 6 basal),
ith wall motion scored 1 for normal, 2 for hypokinetic, 3
or akinetic, 4 for dyskinetic, and 5 for aneurismal, accord-
ng to the guidelines of the American Society of Echocar-
Healthy Controls p Value (HF/HC)DCM
7 11
60.9 5 29.1 2 0.05
7 4 0.05
4 0 0.05
3 0 0.05
1 0 0.055
0 n.d.
3 3 0.142
6 0
6 0
4 0
2 0
2 0
No MI No MI
0/5/2/0 n.d.
34.6 3.8 n.d.
0.05
1,492 33.1
186–2,940 15.0–64.7ts
08
6
5tor blocker; ASS  acetylsalicylic acid; DCM  dilated cardiomyopathy; EF  ejection fraction;
BNP  N-terminal pro–B-type natriuretic peptide; NYHA  New York Heart Association.
2111JACC Vol. 59, No. 23, 2012 Xu et al.
June 5, 2012:2107–17 Micro-RNAs and Cell Therapydiography. WMSI was calculated as the ratio of the sum of
wall motion scores over the total segments scored (24).
Fractional shortening and ejection fraction were calculated
based on the left ventricular end-systolic dimension and
end-diastolic dimension obtained from the middle short-
axis view in M-mode.
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Figure 2 Validation of Micro-RNA Expression
(A to H) Expression of micro-RNAs (miRs) was determined by TaqMan polymerase
trols (HC) (n11), patients with ischemic cardiomyopathy (ICM) (n  11), patients
thy (DCM) (n  7). *p 0.05 versus HC; (1-way analysis of variance with post-hocStatistical analysis. Distributions of categorical variables
were tested by chi-square test or Fisher’s exact test. Con-
tinuous variables are reported as mean  SE, if not stated
otherwise. All variables were tested for homogeneity of vari-
ance by Levènes test. If heterogeneity of variance was present,
analysis of variance (ANOVA) was followed by Dunnett-T3
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Micro-RNAs and Cell Therapy June 5, 2012:2107–17post hoc analysis. Otherwise, groups were compared using
ANOVA followed by Bonferroni correction. Correlations
were analyzed by Spearman test. The specific test used to
analyze the data is indicated in the figure legends.
Experimental studies were analyzed using 1-way ANOVA
(least significant difference test) for the comparison among 3
groups, and independent sample t-test for comparison between
groups. Probability values of 0.05 were considered signif-
cant and 2-sided tests were performed. Data are presented as
eans, and error bars depict the SEM.
esults
icro-RNA expression in patient-derived BMC. For
nalysis of the miR expression patterns, BMCs were iso-
ated from healthy volunteers (n  6) or patients with AMI
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Figure 3 Correlation of Micro-RNA Expression With Age
(A to F) Micro-RNA (miR) expression was measured in bone marrow–derived mono
patients by TaqMan polymerase chain reaction and was correlated to the age of th
RNA expression was determined by miR array in BMCs isolated from young (6 wee
(t-test).r ischemic cardiomyopathy (ICM) (n  6) (Online
Table 1). The group of healthy volunteers was significantly
younger, and did not take any medication (Online Table 1).
Analysis of the miR microarray revealed that several miRs
are regulated in BMCs isolated in all patients (n  6)
compared to those isolated from healthy volunteers (Online
Tables 2 and 3, Fig. 1). Among others, the expression of the
pro-apoptotic miR-34a and the hypoxia-regulated miR-210
were increased (Fig. 1B). Moreover, the expression of
miR-1274a and miR-1274b, whose functions are unknown,
were up-regulated (Fig. 1B).
To confirm the regulation of miR expression in patient-
derived BMCs compared with healthy controls and to
obtain further insights into the specific influence of the
underlying disease on BMC miR expression, we determined
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June 5, 2012:2107–17 Micro-RNAs and Cell Therapythe expression of selected miRs in a confirmation cohort of
11 healthy volunteers, 11 patients with ICM, 8 patients
with AMI, and 7 patients with nonischemic heart failure
(DCM) (Table 1). Consistent with the increased expression
of miR-210 shown in the profiling, miR-210 was signifi-
cantly increased in all patients (n  26) compared with
ealthy controls (139  8% increase; p  0.012) (Online
ig. 1). The expression of miR-210 was also increased in
MCs isolated from patients with ICM, AMI, and DCM;
owever, the differences failed to achieve statistical signifi-
ance (Fig. 2A). Micro-RNA-34a levels, which were among
he most profoundly up-regulated in the profile, were
ignificantly increased in all patients (238  18%;
0.001) and in patients with AMI, ICM, and DCM
ompared with healthy controls (Fig. 2B). Micro-RNA-
274a and miR-1274b were significantly increased in
MCs from patients compared with the expression in
MCs isolated from healthy volunteers (141  12%; p 
.043 and 149  11%; p  0.008, respectively). Although
iR-1274a only showed a trend toward higher expression
n patients with AMI and ICM (Fig. 2C), miR-1274b was
ignificantly increased in AMI and ICM patient-derived
MCs compared with healthy controls (Fig. 2D).
Moreover, we determined the expression of additional
iRs, such as members of the let-7 family, miR-1260, and
iR-30b. Let-7b and let-7c were significantly increased in
atient-derived BMCs compared with healthy controls
Online Fig. 1). Let-7b as well as let-7c were significantly
ncreased in BMCs from patients with AMI compared with
ealthy controls (Figs. 2E and 2F), whereas only a trend
B
A
5-AZA-dc
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MK
100bp
200bp
Healthy
Controls (HC)
HC-1 HC
10 20 2010 10 20
MU U
µl
10 2010 20 2010µl
CMI-1 CM
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with CMI
Figure 4 DNA Methylation of the MiR-34a Promoter
(A) Validation of the DNA methylation specific polymerase chain reactions (PCRs)
methylated (indicated by “M”) and unmethylated (indicated by “U”) in bone marrow
examples are shown. Negative controls (Neg) were products from methylation-spec
used as positive control (Pos).towards increased expression was detected in ICM and
DCM patient-derived BMCs. Micro-RNA-1260 was also
increased comparing BMCs isolated from all patients with
healthy controls (148  12%; p  0.019); however, no
significant differences were detected between groups
(Fig. 2G). Micro-RNA-30b, which regulates invasion (25),
and miR-92a, which was previously shown to inhibit neovas-
cularization after ischemia (26), were not regulated in BMCs
isolated from patients with either AMI, ICM, or DCM
compared with healthy controls (Fig. 2H) (data not shown).
Influence of age on miR levels in BMC. Because some of
the up-regulated miRs were associated with aging (20,27),
we determined the influence of age on the expression of
miRs in BMCs. Micro-RNA-1274b, miR-34, miR-1260,
and the members of the let-7 family showed a highly
significant association with age (Figs. 3A to 3E). This
association was also observed when only patients with
cardiac disease were included in the analysis (data not
shown). The age dependency of let-7b, let-7c, and miR-34a
was confirmed in mice BMCs (Figs. 3G to 3I), suggesting
that these miRs are influenced by age.
Regulation of miR-34a expression in BMC is independent
on promoter DNAmethylation. Because recent studies sug-
gested that miR-34 expression is regulated by silencing
DNA methylation of CpG islands (23,28), we evaluated the
DNA methylation patterns of the miR-34a promoter in
BMCs isolated from healthy controls and patients with
congestive heart failure. Therefore, we used previously
described MSPs (23), which were validated by using trans-
formed cells. Consistent with previous studies, transformed
- - +
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M
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10 20 201010 20 20100
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Micro-RNAs and Cell Therapy June 5, 2012:2107–17cells showed high DNA methylation of the miR-34a
promoter, which was reduced by treatment of the cells with
the DNA methylation inhibitor azaC (Fig. 4A). However,
no DNA methylation was detected in any of the BMC
samples (Fig. 4B), suggesting that miR-34a expression is
not regulated at the level of DNA methylation in BMCs.
Inhibition of miR-34a expression prevents cell death of
BMCs. Because miR-34a is known to induce apoptosis in
several cell types and was highly expressed in BMCs
(Online Fig. 2A), we determined the influence of miR-34a
inhibition on BMC survival. Because cholesterol-modified
antagomirs directed against miR-34a only insufficiently
repressed the miR (data not shown), we used LNA-
modified anti-miRs (29), which dose-dependently inhibited
miR-34a expression (Fig. 5A). LNA-34 most efficiently
inhibited miR-34a (80%) and miR-34b (50%), whereas
the other family members, miR-34c and miR-449a, were
only slightly reduced, and miR-449b was unchanged
(Online Figs. 2A and 2B). LNA-34a significantly inhibited
hydrogen peroxide and serum depletion-induced cell death
(Figs. 5B and 5C, Online Fig. 3). In addition, a significant
increase of SDF-1–induced migration was observed in
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Figure 5 Inhibition of MiR-34 Improves BMC Survival
(A) Micro-RNA-34a (miR-34a) was inhibited by incubating bone marrow–derived mo
determined by TaqMan polymerase chain reaction (n  9, n  3 to 6 [t-test]). (B)
control anti-miR (locked nuclear acid [LNA]-co, 500 nM) and anti-miR-34a (LNA-34a
variance [ANOVA]and Fisher’s least significant difference test [LSD]). (C) Cell deat
nM) and anti-miR-34a (LNA-34a, 500 nM). *p 0.05 versus PBS-0% FCS and LNA
incubated with PBS, LNA-co, or LNA-34a (500 nM) for 36 h and invasion was stim
*p 0.05 versus LNA-coSDF-1 (n  12 from 6 donors; 1-way ANOVA and FisherLNA-34a treated BMCs (Fig. 5D). Consistent with a
pro-apoptotic function of miR-34a, we demonstrated that
overexpression of miR-34a in healthy volunteer-derived
BMCs increased cell death (Figs. 6A and B).
Micro-RNA-34a is known to regulate various target
genes that control apoptosis and cell cycle progression, such
as Sirt1 (30), Bcl2, cyclins (CCN), and cyclin-dependent
kinases (CDKs) (19). Therefore, we determined the regu-
lation of miR-34a targets genes in BMCs. Overexpression
of miR-34a in BMCs reduced the mRNA expression of
Sirt1 by around 10% and repressed CDK4, CDK6, and the
cyclins, CCN1 and CCN3, by 10% to 20%, whereas the
expression of the cell cycle inhibitor p21 was not changed
(Fig. 6C). The down-regulation of CDK4 and CCN1 by
miR-34 was confirmed by Western blot (Fig. 6D).
Inhibition of miR-34a expression ex vivo improves the
therapeutic benefit of cell therapy. Inhibition of BMC
apoptosis by anti-miR-34a may provide a strategy to en-
hance the therapeutic benefit of BMC therapy. Therefore,
we pre-treated human BMCs with LNA-34a, followed by
injection in infarcted nude mice. Although the extent of
functional impairment after infarction was similar in all 3
C
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eath was induced by 200 M H202 (12 h) in phosphate-buffered saline (PBS),
nM). *p 0.05 versus LNA-co  hydrogen peroxide (n  9; 1-way analysis of
induced by starvation (0% FCS) for 48 h in PBS, control anti-miR (LNA-co, 500
FCS (n  9 from 2 donors; 1-way ANOVA and Fisher’s LSD). (D) BMCs were
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cardiac function after 2 weeks of follow-up (Fig. 7). In the
group of mice that had been injected with LNA-34a
pre-treated BMCs, a significant further increase in func-
tional recovery was observed (Fig. 7), suggesting that ex vivo
inhibition of miR-34a improves the therapeutic effect of
BMC cell therapy.
Discussion
The data of the present study demonstrate that BMCs
isolated from patients with AMI or heart failure show a
distinct expression profile of miRs compared with healthy
donor derived BMCs. Particularly, the pro-apoptotic miR-
34a was significantly increased in patient-derived BMCs.
Inhibition of miR-34a improved cell survival, whereas
overexpression induced cell death in BMCs in vitro. Ex vivo
pre-incubation of BMCs with a miR-34a inhibitor in-
creased the capacity of the injected BMCs to augment
cardiac function in mice after AMI. The miR-34 family is
known for its function as a tumor suppressor (19,31).
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Figure 6 Micro-RNA-34a Induced Cell Death and Reduced the E
Pre-micro-RNA(miR)-34a (5 nM) or control precursor (pre-co) were overexpressed b
after 48 h. *p 0.05 versus pre-co (n  6 to 9 from 2 different donors; t-test). (C
cells (BMCs) after 48 h (n  11 to 14 from 3 different donors; t-test). (D) Repres
ing pre-miR-34a (5 nM) for 48 h. CDK  cyclin-dependent kinases; RNU48  smactopic overexpression of miR-34a induced apoptosis andcell cycle arrest in primary- and tumor-derived cell lines
(31–33). Additionally, miR-34a is involved in oncogene-
induced senescence (18) and is increased in senescent
endothelial cells in vitro (27). These data are in accordance
with our study showing that miR-34a regulates BMC
survival in vitro and that miR-34a expression is associated
with the age of the donor of the BMCs in humans and in
mice. The mechanism underlying the increased miR-34a
expression in BMCs of patients with heart disease or in aged
mice is unclear. It is known that p53 induces the expression
of the transcripts encoding miR-34 family members
(31,34,35). Moreover, the expression of miR-34 can be
increased independently of p53 (18) and is also regulated by
DNA methylation of CpG islands of the miR-34 promoters
(23,28,36). However, when we analyzed the DNA methyl-
ation of the promoter of miR-34a, no methylation was
detected in any of the BMC samples, suggesting that age
and disease either transcriptionally activate the miR-34a
promoter or enhance the processing of miR-34a.
Consistent with previous studies (19,30), miR-34a re-
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human BMCs. Of note, although the global gene expres-
sion pattern shown in the present study was consistent with
the previous findings, the extent of target gene regulation
was modest. This may in part be explained by the prefer-
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Figure 7 Ex Vivo Pre-Treatment of BMC With LNA-34a
Improves the Therapeutic Benefit of Cell Therapy
(A to C) Bone marrow–derived mononuclear cells (BMCs) were pre-treated with
phosphate-buffered saline (PBS) or 500 nM locked nuclear acid (LNA)-34a for
24 h. Directly after induction of acute infarction in nude mice, PBS alone or
equal numbers of PBS-treated or LNA-34a-treated BMCs were injected. Cardiac
function was monitored by echocardiography after 2 weeks. N 11 per group.
*p 0.05 versus BMC  PBS (1-way analysis of variance and Fisher’s least
significant difference test). WMSI  wall motion score index.ential inhibition of protein translation compared with directRNA degradation by miRs as well as the inefficient over-
expression of the precursor by electroporation in BMCs.
In addition to miR-34, several other miRs were dysregu-
lated in patient-derived BMCs. Micro-RNA-210 was in-
creased in the profile and in the confirmation study.
Micro-RNA-210 is up-regulated by hypoxia in vitro and in
plasma of critically ill patients with acute kidney injury (37).
Because miR-210 suppresses mitochondrial functions (21) and
mitochondrial function was shown to be essential for pro-
angiogenic cell migration (38), we hypothesized that the
increase in miR-210 levels might control BMC functions.
However, blocking miR-210 neither affected mitochondrial
membrane potential nor did it influence BMC survival and
functions in vitro (Online Fig. 5).
The let-7 family members, let-7b and let-7c, were also
significantly increased, particularly in BMCs from patients
with AMI. Let-7b is known to reduce neural stem cell
numbers and to suppress self-renewal by targeting the
transcriptional regulator Hmga2 (20), and let-7c represses
self-renewal genes in embryonic stem cells (39). Because
let-7 expression was highly associated with age in the
patient population and was increased in the BMCs isolated
from old versus young mice, one may speculate that this miR
may contribute to age-induced progenitor cell senescence.
Interestingly, let-7 family members (let-7a/b/c/d/f) reduced
the expression and release of vascular endothelial growth factor
and interleukin-6 (40). Because the release of pro-angiogenic
cytokines is considered a major mechanism underlying the
BMC-mediated improvement of neovascularization and repair
processes (41), the repression of these cytokines by augmented
levels of let-7 family members may contribute to the impaired
functionality of patient-derived BMCs.
Of note, the regulation of miRs in BMCs isolated from
patients with AMI did not entirely reflect the miR expression
patterns reported in a recent study demonstrating that miR-
150 was significantly reduced in BMCs isolated from mice
after AMI (42). Although miR-150 was slightly reduced in
BMCs from patients with AMI (Online Fig. 6), the differ-
ences were not statistically significant. Other miRs, such as the
let-7 family, which were also down-regulated in mice after
AMI (42), were significantly increased in our patient cohort.
One may speculate that the differences between our study and
the miR expression patterns after AMI in mice, at least in part,
might be related to the fact that patients (but not young healthy
mice) are additionally exposed to risk factors, which might
influence miR expression patterns in the bone marrow. However,
our patient cohorts were rather small, and further confirmation in
larger patient cohorts is warranted.
Together, our study provides novel insights into the
dysregulated miR pattern of patient-derived BMCs. Inhi-
bition of the elevated levels of the pro-apoptotic miR-34a ex
vivo improved the functional benefit of transplanted BMCs
in vivo and might comprise a strategy to enhance the effect
of autologous cell therapy. In addition, the de-regulation of
other miRs, particularly the senescence associated let-7
family members, may additionally impair the function of the
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old and diseased patients.
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